On Tuesday, Shares of RAIT Financial Trust (NYSE:RAS), lost -26.67% to $2.97.
RAIT Financial Trust, declared its fourth quarter cash dividend on its common shares and reaffirmed its fourth quarter 2015 guidance regarding its predictable cash available for distribution (“CAD”).
Scott Schaeffer, RAIT’s Chairman and CEO, said, “We are reaffirming RAIT’s Q4 2015 CAD guidance of $0.22-$0.23 per common share as RAIT’s core lending platform continues to perform. We are also ongoing with our formerly declared capital recycling strategy. However, the Board has reviewed RAIT’s quarterly common dividend level and determined that a reduction to $0.09 per common share is appropriate in the current capital market environment. This action by the Board generates immediate capital availability to support the lending platform while maintaining RAIT’s capital flexibility.”
Fourth Quarter Cash Dividend – On December 7, 2015, RAIT’s Board of Trustees declared a fourth quarter 2015 cash dividend on RAIT’s common shares of $0.09 per common share. The dividend will be paid on January 29, 2016 to holders of record on January 8, 2016. The ex-dividend date is January 6, 2016.
RAIT Financial Trust operates as a self-managed and self-advised real estate investment trust (REIT). The company, through its auxiliaries, invests in, manages, and services real estate-related assets with a focus on commercial real estate.
Shares of Walt Disney Co (NYSE:DIS), declined -1.14% to $112.53, during its last trading session.
The next evolution of the Marvel Cinematic Universe brings a founding member of The Avengers to spectacular life for the first time in Marvel’s “ANT-MAN,” the pulse-pounding action adventure now available to own on Digital 3D, Digital HD and Disney Movies Anywhere, and on Blu-ray 3D Combo Pack, Blu-ray, DVD, Digital SD and On-Demand Dec. 8, 2015. Armed with the astonishing ability to shrink in scale but improvement in strength, master thief Scott Lang must embrace his inner-hero and assist his mentor Dr. Hank Pym plan and pull off a heist that will save the world. Full of humor and heart, Marvel’s “ANT-MAN” is big entertainment for the whole family and the perfect gift for movie fans this holiday season on Blu-ray and Digital HD!
Certified “Fresh” on Rotten Tomatoes and grossing a heroic $519 million dollars (BoxOfficeMojo.com) at the worldwide box office, Marvel’s “ANT-MAN” climbs to stunning new heights on Blu-ray 3D, featuring thrillingly immersive 3D high definition picture and sound that puts viewers inside the adventure like never before. The in-home releases also come equipped with mind-blowing bonus features, counting “Making Of An Ant-Sized Heist: A How-To Guide,” a fast-paced behind-the-scenes look at how to pull off a heist movie, focusing on Scott Lang’s hilarious heist “family,” Ant-Man’s costume, and the film’s amazing stunts and effects; “Let’s Go To The Macro verse,” a fascinating look at creating the world from Ant-Man’s perspective, from macro photography through the subatomic; “WHIH News Front,” a hard-hitting collection of content, counting a glimpse at the future of Pym Technologies with Darren Cross, anchor Christine Everhart’s interview with soon-to-be-released prisoner Scott Lang on his notorious Vista Corp heist; Deleted & Extended Scenes; Gag Reel; Audio Commentary By Peyton Reed And Paul Rudd, and more!
The Walt Disney Company, together with its auxiliaries, operates as an entertainment company worldwide. The company operates broadcast and cable television networks, domestic television stations, and radio networks and stations; and is involved in the television production and television distribution operations.
Finally, Gilead Sciences, Inc. (NASDAQ:GILD), ended its last trade with 0.60% gain, and closed at $103.53.
Gilead Sciences, declared results from a pre specified interim analysis of a Phase 3 study (Study 115) evaluating Zydelig® (idelalisib) in combination with bendamustine and rituximab (BR) for patients with formerly treated CLL. The analysis found a 67 percent reduction in the risk of disease progression or death (progression-free survival, PFS) in patients receiving Zydelig plus BR contrast to BR alone (hazard ratio (HR) = 0.33; 95 percent CI: 0.24, 0.45; p<0.0001). Additionally, all secondary endpoints, counting overall survival (OS), achieved statistical significance in this interim analysis. Detailed results were presented recently during the late-breaking abstracts session at the Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida (#LBA-5).
“These new findings add to the role of idelalisib-containing regimens for the treatment of relapsed CLL,” said Andrew D. Zelenetz, MD, PhD, Medical Oncologist and Vice Chair, Medical Informatics, Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center. “In this Phase 3 study, adding idelalisib to BR offered not only statistically noteworthybut clinically meaningful improvements in progression-free and overall survival contrast to BR, a current standard of care in relapsed/refractory CLL. Further, idelalisib treatment also benefitted patients with genetic factors associated with a poorer prognosis.”
Zydelig is approved in the United States in combination with rituximab for patients with relapsed CLL for whom rituximab alone would be considered appropriate therapy due to comorbidities. Based on the Study 115 results, Gilead plans to submit supplemental regulatory filings in the U.S. and Europe early next year.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.